11 / 48
Teff gene signature is a more sensitive biomarker of PFS than PD-L1 IHC
At a similar prevalence, Teff gene expression identified a larger number of patients who
experienced a significant PFS benefit with atezolizumab therapy
Atezolizumab Clinical Benefit in
Subgroups Defined by Teff Gene
Signature and PD-L1 IHC (SP142)
in OAK
Kowanetz et al. WCLC 2017.
11
PFS
OS
PD-L1 IHC
(SP142) TC1/2/3
or IC1/2/3
Teff Signature
≥ Median
PD-L1 IHC
(SP142)
TC1/2/3 or
IC1/2/3
Teff Signature
≥ Median
Prevalence
55%
51%
55%
51%
HR
(95% CI)
0.93
(0.76, 1.15)
0.73
(0.58, 0.91)
0.74
(0.58, 0.95)
0.59
(0.46, 0.76)
HR (95% CI)
BEP (N = 753)
0.94
(0.81, 1.10)
0.71
(0.59, 0.85)